← back to search

Sandy Liu

Diamond Materials (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Genomics and Diagnostics, and Prostate Cancer Treatment and Research.
h-index
29
citations
3,936
works
151
NIH funding
primary concept
email

Recent publications

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
npj Digital Medicine 2022cited by 185position: middledoi
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Clinical Cancer Research 2022cited by 107position: middledoi
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer 2022cited by 27position: middledoi
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer 2022cited by 23position: middledoi
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
European Urology Oncology 2021cited by 62position: middledoi
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
British Journal of Urology 2021cited by 28position: middledoi
Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer
British Journal of Urology 2021cited by 5position: middledoi
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
The Journal of Urology 2020cited by 61position: middledoi
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
Cancer 2019cited by 89position: middledoi
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials
European Urology 2019cited by 61position: middledoi
Giant symptomatic gastric lipoma
International Journal of Surgery Case Reports 2018cited by 22position: middledoi
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
Clinical Genitourinary Cancer 2017cited by 52position: firstdoi
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence
Lung 2015cited by 74position: middledoi
Src as the link between inflammation and cancer
Frontiers in Physiology 2014cited by 74position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Yousef Zakharia · SUNY Upstate Medical University2 papers (2022–2022)Alexandra Drakaki · University of Colorado Denver2 papers (2017–2022)Marc Matrana · Ochsner Health System1 papers (2022–2022)Karim Chamie · UCLA Medical Center1 papers (2017–2017) · 1 papers (2015–2015)Pedro C. Barata · Southwestern Medical Center1 papers (2022–2022)Stephen J. Pandol · Nanjing Medical University1 papers (2014–2014)Tanya Jindal · University of California, San Francisco1 papers (2022–2022)Nizar M. Tannir · The University of Texas MD Anderson Cancer Center1 papers (2022–2022)Leonidas Nikolaos Diamantopoulos · Northwell Health1 papers (2022–2022)Robert J. Motzer · Texas Oncology1 papers (2022–2022)Alessio Cortellini · Università degli Studi del Piemonte Orientale “Amedeo Avogadro”1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2014–2014)Ulka N. Vaishampayan · The Barbara Ann Karmanos Cancer Institute1 papers (2022–2022)Nishita Tripathi · Wayne State University1 papers (2022–2022)Montaser Shaheen · The University of Texas at San Antonio Health Science Center1 papers (2022–2022)Dimitra Rafailia Bakaloudi · Seattle University1 papers (2022–2022)Roubini Zakopoulou · National and Kapodistrian University of Athens1 papers (2022–2022)